Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2003 Mar;88(3):197–200. doi: 10.1136/adc.88.3.197

Use of methotrexate in juvenile idiopathic arthritis

A Ramanan 1, P Whitworth 1, E Baildam 1
PMCID: PMC1719480  PMID: 12598376

Abstract

Methotrexate (MTX) has transformed the outlook for children with juvenile idiopathic arthritis (JIA). Most of the evidence from uncontrolled clinical trials suggests that MTX is an effective agent for treating active JIA. Data from controlled clinical trials suggests that MTX has statistically significant effects on patient centred disability measures in JIA patients with active arthritis. Although we would like a much larger study directed evidence base for our use of the drug, the studies that have been done are sound and have been followed by a change in clinical expectations and advice that speak of qualitative evidence from clinical practice, confirming the scientifically acquired data. Randomised controlled multicentre trials using sufficient numbers of patients, including functional assessment and quality of life measures, are needed to confirm the long term efficacy and safety of MTX in JIA.

Full Text

The Full Text of this article is available as a PDF (87.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baggott J. E., Morgan S. L., Ha T. S., Alarcón G. S., Koopman W. J., Krumdieck C. L. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol. 1993 Mar-Apr;11 (Suppl 8):S101–S105. [PubMed] [Google Scholar]
  2. Baugh C. M., Krumdieck C. L., Nair M. G. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun. 1973 May 1;52(1):27–34. doi: 10.1016/0006-291x(73)90949-2. [DOI] [PubMed] [Google Scholar]
  3. Cleary A. G., McDowell H., Sills J. A. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child. 2002 Jan;86(1):47–49. doi: 10.1136/adc.86.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cronstein B. N., Eberle M. A., Gruber H. E., Levin R. I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2441–2445. doi: 10.1073/pnas.88.6.2441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cutolo M., Sulli A., Pizzorni C., Seriolo B., Straub R. H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001 Aug;60(8):729–735. doi: 10.1136/ard.60.8.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feldkamp M., Carey J. C. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993 Jun;47(6):533–539. doi: 10.1002/tera.1420470605. [DOI] [PubMed] [Google Scholar]
  7. Giannini E. H., Brewer E. J., Kuzmina N., Shaikov A., Maximov A., Vorontsov I., Fink C. W., Newman A. J., Cassidy J. T., Zemel L. S. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992 Apr 16;326(16):1043–1049. doi: 10.1056/NEJM199204163261602. [DOI] [PubMed] [Google Scholar]
  8. Gottlieb B. S., Keenan G. F., Lu T., Ilowite N. T. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997 Dec;100(6):994–997. doi: 10.1542/peds.100.6.994. [DOI] [PubMed] [Google Scholar]
  9. Graham L. D., Myones B. L., Rivas-Chacon R. F., Pachman L. M. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr. 1992 Mar;120(3):468–473. doi: 10.1016/s0022-3476(05)80923-0. [DOI] [PubMed] [Google Scholar]
  10. Gruber H. E., Hoffer M. E., McAllister D. R., Laikind P. K., Lane T. A., Schmid-Schoenbein G. W., Engler R. L. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation. 1989 Nov;80(5):1400–1411. doi: 10.1161/01.cir.80.5.1400. [DOI] [PubMed] [Google Scholar]
  11. Halle F., Prieur A. M. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol. 1991 May-Jun;9(3):297–302. [PubMed] [Google Scholar]
  12. Harel L., Wagner-Weiner L., Poznanski A. K., Spencer C. H., Ekwo E., Magilavy D. B. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993 Oct;36(10):1370–1374. doi: 10.1002/art.1780361007. [DOI] [PubMed] [Google Scholar]
  13. Huang J. L. Methotrexate in the treatment of children with chronic arthritis--long-term observations of efficacy and safety. Br J Clin Pract. 1996 Sep;50(6):311–314. [PubMed] [Google Scholar]
  14. Jundt J. W., Browne B. A., Fiocco G. P., Steele A. D., Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993 Nov;20(11):1845–1849. [PubMed] [Google Scholar]
  15. Kremer J. M. Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34 (Suppl 2):26–29. [PubMed] [Google Scholar]
  16. Kremer J. M. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol. 1994 Jan;21(1):1–5. [PubMed] [Google Scholar]
  17. Lovell D. J., Giannini E. H., Reiff A., Cawkwell G. D., Silverman E. D., Nocton J. J., Stein L. D., Gedalia A., Ilowite N. T., Wallace C. A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763–769. doi: 10.1056/NEJM200003163421103. [DOI] [PubMed] [Google Scholar]
  18. Milunsky A., Graef J. W., Gaynor M. F., Jr Methotrexate-induced congenital malformations. J Pediatr. 1968 Jun;72(6):790–795. doi: 10.1016/s0022-3476(68)80430-5. [DOI] [PubMed] [Google Scholar]
  19. Ostensen M., Hartmann H., Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol. 2000 Aug;27(8):1872–1875. [PubMed] [Google Scholar]
  20. Ravelli A., Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. 2000 Aug;27(8):1830–1833. [PubMed] [Google Scholar]
  21. Ravelli A., Ramenghi B., Di Fuccia G., Ruperto N., Zonta L., Martini A. Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. Acta Paediatr. 1994 Apr;83(4):428–432. doi: 10.1111/j.1651-2227.1994.tb18135.x. [DOI] [PubMed] [Google Scholar]
  22. Ravelli A., Viola S., Ramenghi B., Beluffi G., Zonta L. A., Martini A. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr. 1998 Aug;133(2):262–265. doi: 10.1016/s0022-3476(98)70231-8. [DOI] [PubMed] [Google Scholar]
  23. Ravelli A., Viola S., Ramenghi B., Di Fuccia G., Ruperto N., Zonta L., Martini A. Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. Clin Rheumatol. 1995 May;14(3):322–326. doi: 10.1007/BF02208347. [DOI] [PubMed] [Google Scholar]
  24. Rose C. D., Singsen B. H., Eichenfield A. H., Goldsmith D. P., Athreya B. H. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1990 Oct;117(4):653–659. doi: 10.1016/s0022-3476(05)80709-7. [DOI] [PubMed] [Google Scholar]
  25. Schmeling H., Mathony K., John V., Keysser G., Burdach S., Horneff G. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis. 2001 Apr;60(4):410–412. doi: 10.1136/ard.60.4.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Singsen B. H., Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am. 1997 Nov;23(4):811–840. doi: 10.1016/s0889-857x(05)70362-8. [DOI] [PubMed] [Google Scholar]
  27. Sonneveld P., Schultz F. W., Nooter K., Hählen K. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother Pharmacol. 1986;18(2):111–116. doi: 10.1007/BF00262278. [DOI] [PubMed] [Google Scholar]
  28. Speckmaier M., Findeisen J., Woo P., Hall A., Sills J. A., Price T., Hollingworth P., Craft A., Ansell B. M. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol. 1989 Nov-Dec;7(6):647–650. [PubMed] [Google Scholar]
  29. Symmons D. P., Jones M., Osborne J., Sills J., Southwood T. R., Woo P. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol. 1996 Nov;23(11):1975–1980. [PubMed] [Google Scholar]
  30. Truckenbrodt H., Häfner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 1986 Jun;29(6):801–807. doi: 10.1002/art.1780290616. [DOI] [PubMed] [Google Scholar]
  31. Wallace C. A., Bleyer W. A., Sherry D. D., Salmonson K. L., Wedgwood R. J. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1989 Jun;32(6):677–681. doi: 10.1002/anr.1780320604. [DOI] [PubMed] [Google Scholar]
  32. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  33. Woo P., Southwood T. R., Prieur A. M., Doré C. J., Grainger J., David J., Ryder C., Hasson N., Hall A., Lemelle I. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000 Aug;43(8):1849–1857. doi: 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  34. van Ede A. E., Laan R. F., Rood M. J., Huizinga T. W., van de Laar M. A., van Denderen C. J., Westgeest T. A., Romme T. C., de Rooij D. J., Jacobs M. J. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001 Jul;44(7):1515–1524. doi: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES